IDH1 and cholangiocarcinoma: To date, dozens of small molecules of IDH1/IDH2 inhibitors are under investigation, of which ivosidenib (AG-120) has been approved for the treatment of IDH1 mutated cholangiocarcinoma and acute myeloid leukaemia31–33.